Trulicity (Dulaglutide): What It Is, How It Works & Who Should Take It (2026 Guide)

What is Trulicity?

Trulicity is the brand name for dulaglutide, a prescription injectable medication approved by the US Food and Drug Administration for the treatment of type 2 diabetes in adults and in children aged 10 and older. Trulicity belongs to a class of drugs called GLP-1 receptor agonists. It is given as a once-weekly subcutaneous injection using a single-use prefilled pen that has no dose dial and no visible needle.

Trulicity is manufactured by Eli Lilly and Company and was first approved by the FDA in September 2014. Since then, its approved uses have been expanded to include cardiovascular risk reduction in people with type 2 diabetes and established heart disease or multiple risk factors.

What is Trulicity in one sentence?

Trulicity is a once-weekly injection of dulaglutide — a GLP-1 receptor agonist made by Eli Lilly — used to help adults and older children with type 2 diabetes control their blood sugar and, for certain adult patients, reduce the risk of heart attack and stroke.

Is Trulicity a medication or a device?

Both, technically. The medication is dulaglutide, the active ingredient. The device is the single-use auto-injector pen that Eli Lilly packages the medication in. Each Trulicity pen delivers one weekly dose; the pen is disposed of after use in a sharps container.

What is Trulicity used for?

Trulicity is approved by the FDA for three distinct clinical uses:

Blood sugar control in type 2 diabetes — improving glycemic control in adults with type 2 diabetes as an addition to diet and exercise. Trulicity is commonly prescribed alongside metformin and may be used with other diabetes medications including sulfonylureas, thiazolidinediones, SGLT2 inhibitors, and insulin.
Cardiovascular risk reduction — reducing the risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. This expanded indication was added to the label based on the REWIND trial.
Pediatric type 2 diabetes — improving glycemic control in children aged 10 years and older with type 2 diabetes, a relatively recent expansion that made Trulicity the first weekly GLP-1 approved for this age group.

What is Trulicity NOT used for?

Trulicity is not approved for the treatment of type 1 diabetes, diabetic ketoacidosis, or chronic weight management. It should not be used as a substitute for insulin in patients who require insulin therapy, and it has no studied role in patients without diabetes. If weight loss is your primary goal, see our Trulicity weight loss guide — it explains why purpose-built weight loss GLP-1s like Wegovy and Zepbound are the evidence-based option.

Is Trulicity used for prediabetes?

No. Trulicity is not approved for prediabetes. Management of prediabetes centers on lifestyle changes (diet, exercise, weight loss) and, in some patients, metformin. GLP-1 medications are generally reserved for patients who have progressed to type 2 diabetes.

Trulicity drug class

Trulicity belongs to the GLP-1 receptor agonist (GLP-1 RA) drug class, sometimes also called "incretin mimetics" or simply "GLP-1 drugs." Other medications in the same class include:

Ozempic (semaglutide) — weekly, Novo Nordisk
Wegovy (semaglutide, weight management) — weekly, Novo Nordisk
Rybelsus (oral semaglutide) — daily oral, Novo Nordisk
Victoza (liraglutide) — daily, Novo Nordisk
Saxenda (liraglutide, weight management) — daily, Novo Nordisk
Byetta (exenatide) — twice daily, AstraZeneca
Bydureon BCise (exenatide extended release) — weekly, AstraZeneca

A closely related class, dual GIP/GLP-1 receptor agonists, activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. Tirzepatide — sold as Mounjaro for diabetes and Zepbound for weight management — is currently the only drug in this class. Tirzepatide is not technically a GLP-1 drug on its own but is often grouped with them in clinical conversations.

Is Trulicity a GLP-1 medication?

Yes. Trulicity is a GLP-1 receptor agonist — a drug that activates the GLP-1 receptor the same way the natural GLP-1 hormone does, but with a much longer duration of action so it can be dosed once weekly instead of multiple times per day.

How does Trulicity work? (Mechanism of action)

Trulicity's active ingredient, dulaglutide, mimics a gut hormone called glucagon-like peptide-1 (GLP-1). Your body naturally releases GLP-1 after meals to help regulate blood sugar. Dulaglutide binds to the same receptors and produces a sustained, week-long version of that response. Its mechanism of action involves four separate effects:

Stimulates insulin release when blood sugar is high. Dulaglutide causes the pancreas to release more insulin — but only when glucose levels are elevated. This glucose-dependent action is why GLP-1 drugs carry a low risk of hypoglycemia compared to sulfonylureas or insulin.
Suppresses glucagon when glucose is high. Glucagon is the hormone that raises blood sugar. Trulicity reduces inappropriate glucagon release from the pancreas's alpha cells in the fed state, limiting the liver's glucose output.
Slows gastric emptying. Food stays in the stomach longer, which blunts the post-meal blood sugar spike and extends feelings of fullness. This mechanism is largely responsible for the modest weight loss seen on Trulicity, and also for the nausea some patients experience early in treatment.
Reduces appetite signaling. GLP-1 receptors are expressed in areas of the brain that regulate hunger and satiety. Activation of those receptors reduces appetite and the drive to eat between meals, leading to lower caloric intake in most patients.

What does Trulicity do to your body?

From a patient's perspective, the most obvious things Trulicity does are: lower blood sugar (measurable by home glucose monitoring and by A1c tests at your clinician's office), reduce appetite, and make meals more filling. Many patients also notice early GI side effects — particularly nausea — when starting the medication or when increasing the dose. These usually fade within 2–6 weeks of a stable dose.

Trulicity mechanism of action — simple explanation

Imagine the hormone GLP-1 as a messenger that arrives after meals saying "the food is here, release insulin, slow the stomach, you're full." Normally that messenger is very short-lived and gets cleared from the blood in minutes. Dulaglutide is a copy of that messenger engineered to stay active for about a week. One weekly injection keeps the "mealtime" signal going continuously, which is why blood sugar improves and appetite drops.

Trulicity generic name and manufacturer

What is the generic name of Trulicity?

The generic name of Trulicity is dulaglutide. Dulaglutide is a recombinant fusion protein — specifically, a modified human GLP-1 molecule fused to a fragment of a human immunoglobulin G4 (IgG4) antibody. The antibody fragment protects the GLP-1 portion from being broken down too quickly by the body, giving dulaglutide a half-life of about 5 days and allowing once-weekly dosing.

Who makes Trulicity? Is there a generic dulaglutide?

Trulicity is manufactured by Eli Lilly and Company, headquartered in Indianapolis, Indiana. As of 2026, no generic or biosimilar dulaglutide is approved in the United States — only brand-name Trulicity is available. Because dulaglutide is a biologic rather than a small-molecule drug, any generic version would be a biosimilar, and biosimilars take longer to develop and approve than traditional generics. See our generic Trulicity availability section for the latest pricing and alternative options.

What company bought or owns Trulicity?

Eli Lilly developed dulaglutide in-house and has owned Trulicity since its launch. The drug has not been sold, licensed, or transferred to another company. Eli Lilly also manufactures Mounjaro and Zepbound (both tirzepatide), as well as several insulin products (Humalog, Basaglar) and other diabetes and cardiovascular medications.

Is Trulicity insulin?

This is one of the most common questions about Trulicity — and the short answer is no, Trulicity is not insulin. Trulicity does not contain insulin, it is not a type of insulin, and it does not replace insulin in the body. It is a different class of medication that works through a different mechanism.

Why do people think Trulicity is insulin?

Both insulin and Trulicity are given by injection, both are used for diabetes, and both help lower blood sugar. It's a reasonable assumption — but the two drug classes are very different. Insulin directly adds the hormone that moves glucose from the blood into cells; Trulicity instead stimulates the body's own insulin release, slows digestion, and reduces appetite. Trulicity is also much less likely to cause low blood sugar (hypoglycemia) on its own, because its effect on insulin release is glucose-dependent — it mostly acts when your blood sugar is already high.

Can you take Trulicity with insulin?

Yes — and it's common. Many patients with type 2 diabetes take Trulicity together with basal (long-acting) insulin, because the two drugs complement each other: insulin provides a steady background effect, and Trulicity smooths out the post-meal spikes while modestly reducing weight. Combining Trulicity with insulin does raise the risk of hypoglycemia, so insulin doses are typically reduced when a GLP-1 is added. Only your clinician can decide the right combination for you.

Is Trulicity a semaglutide?

Is Trulicity the same molecule as semaglutide?

No. Trulicity is dulaglutide. Semaglutide is a different molecule — it's the active ingredient in Ozempic, Wegovy, and Rybelsus. Both dulaglutide and semaglutide are GLP-1 receptor agonists, both are dosed once weekly as injections (semaglutide also has a daily oral form), and both treat type 2 diabetes — but they are distinct drugs made by different companies (Eli Lilly for dulaglutide, Novo Nordisk for semaglutide). In head-to-head trials, semaglutide has generally produced greater A1c reduction and greater weight loss than dulaglutide at comparable doses.

Is Trulicity older than Ozempic?

Yes. Trulicity (dulaglutide) was approved by the FDA in September 2014. Ozempic (injectable semaglutide) was approved in December 2017. Trulicity has approximately three additional years of post-marketing safety data, though Ozempic's real-world use has grown much more rapidly.

Who should take Trulicity?

Trulicity is an appropriate option for adults and older children with type 2 diabetes who meet one or more of the following profiles:

Type 2 diabetes not adequately controlled on lifestyle changes and metformin alone, or who cannot tolerate metformin.
Type 2 diabetes with established cardiovascular disease (prior heart attack, stroke, or significant risk factors), where Trulicity's FDA-approved cardiovascular risk reduction indication makes it attractive.
Patients for whom a simple once-weekly injection is more realistic than multiple daily doses, and who value the ease-of-use of Trulicity's hidden-needle auto-injector.
Patients 10 years and older with type 2 diabetes, where Trulicity is specifically approved for pediatric use.
Patients who also benefit from modest weight loss as a bonus (typically 3–5% of body weight on average, though results vary).

Who should not take Trulicity?

Trulicity is not appropriate for everyone. The FDA label lists several populations for whom Trulicity is contraindicated or should be used with caution:

Personal or family history of medullary thyroid carcinoma (MTC). Trulicity, like other GLP-1 drugs, carries a boxed warning about the risk of thyroid C-cell tumors based on rodent studies; patients with a history of MTC or multiple endocrine neoplasia syndrome type 2 (MEN 2) should not take it.
Type 1 diabetes. Trulicity is not a substitute for insulin in type 1 diabetes, and its use in this population has not been studied.
Diabetic ketoacidosis. Trulicity should not be used to treat DKA.
Serious hypersensitivity to dulaglutide. Previous anaphylaxis or angioedema is a contraindication.
Severe gastroparesis or significant GI disease. Because Trulicity delays gastric emptying, it can worsen pre-existing gastroparesis or serious GI motility disorders.
Pregnancy, where there is insufficient data. GLP-1 drugs are generally discontinued before planned pregnancy.

For a detailed safety discussion, see the Trulicity side effects guide, which covers common reactions, serious adverse events, and the foods patients commonly report as problematic during treatment.

Frequently asked questions

Is Trulicity a GLP-1?

Yes. Trulicity (dulaglutide) is a GLP-1 receptor agonist. 'GLP-1' stands for glucagon-like peptide-1, a natural gut hormone released after meals that helps the body regulate blood sugar. Trulicity is a long-acting synthetic version that activates the same receptors as natural GLP-1, but lasts about a week in the body so it can be injected once weekly.

What is Trulicity's generic name?

Trulicity's generic name is dulaglutide. It is a recombinant fusion protein that combines a modified GLP-1 molecule with a portion of a human antibody, which gives it a long half-life and allows once-weekly dosing. No generic dulaglutide is currently available in the United States.

Who makes Trulicity?

Trulicity is manufactured by Eli Lilly and Company, based in Indianapolis, Indiana. Eli Lilly also makes Mounjaro (tirzepatide) and Zepbound (tirzepatide for weight management), as well as several insulin products and other diabetes medications.

Is Trulicity the same as Ozempic?

No. Trulicity is dulaglutide (Eli Lilly). Ozempic is semaglutide (Novo Nordisk). Both are once-weekly GLP-1 receptor agonists for type 2 diabetes, but they are different molecules with different potencies and clinical trial results. See our full Trulicity vs Ozempic comparison.

Is Trulicity a type of insulin?

No. Trulicity is not insulin. It does not contain insulin and it does not directly replace insulin. Trulicity is a GLP-1 receptor agonist that stimulates the body's own insulin production (only when blood sugar is high) and also slows digestion and reduces appetite. Patients with type 2 diabetes sometimes take Trulicity together with insulin under a clinician's direction, but the two drug classes work differently.

What does Trulicity do in the body?

Trulicity activates GLP-1 receptors throughout the body, which produces four main effects: (1) increased insulin release from the pancreas when blood sugar is high, (2) decreased glucagon release (the hormone that raises blood sugar), (3) slower gastric emptying so food leaves the stomach more gradually, and (4) reduced appetite signalling in the brain. Together these lower blood sugar and modestly reduce body weight.

How long has Trulicity been on the market?

Trulicity was first approved by the US Food and Drug Administration in September 2014 for the treatment of type 2 diabetes in adults. Its approvals have since been expanded to include cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors, and to include adolescent patients aged 10 years and older.